Researchers have identified that people living with HIV who are unvaccinated for hepatitis B are at higher risk for new hepatitis B infections.
This is according to a study conducted by a group of scientific researchers and shared at the 2022 Conference on Retroviruses and Opportunistic Infections (CROI).
It also revealed that a particular high risk was found among those individuals with hepatitis C.
The study strongly recommends Hepatitis B Virus (HBV) vaccination in HBV seronegative people living with HIV even if they are on dual active HIV/HBV antiviral therapy.
Its conclusion is that both Vaccines and hepatitis B virus (HBV) specific antiretrovirals (ART) may offer protection for people living with HIV (PLWH) against acquiring new HBV infection.
This study is very important especially for the African Region because the burden of hepatitis B infection is highest in this part of the world – the WHO Western Pacific Region and the WHO African Region, record that 116 million and 81 million people, respectively, are chronically infected.
At CROI 2022, the study presented by Mamta Jain from the University of Texas Southwestern Medical Center on behalf of the five authors examined the incidence of HBV and factors which predicted risk for acquiring infection among Persons Living with HIV (PLWH) in the US.
The study included all PLWH with a minimum of 1 to 9 years of follow-up from January 1, 2011, to December 31, 2018.
Patients with no HIV viral load or CD4 counts as well as those with signs of chronic HBV infection were excluded from the study.
Out of 26,152 PLWH, 12,285 were included.
35.2 percent had CD4 below 200 cells/ÂµL, 12.3 percent had HIV viral load less than 50 copies/mL, 42.6percent were HBV immune at study entry.
Within two (2) years of study, 80.6 percent were on an HBV-specific HIV regimen. Overall, 0.49 percent (n= 60; 65 percent non-immune and 52 percent with CD4 less than 200 cell/ÂµL at baseline) developed incident hepatitis B during follow-up.
But in contrast to other studies, the authors did not observe a protective effect of HBV specific medication at baseline for development of new HBV infection in follow-up. The poster however did not provide information which HBV specific medication was used.
Meanwhile, prior studies from the Netherlands demonstrated a persistent risk for new HBV infections in PLWH receiving 3TC as sole HBV active agent but not necessarily in tenofovir-treated patients who were sixteen (16).
Moreover, the US investigators showed that patients with HCV infection were at increased risk for acquiring HBV infection underlining the need for HBV vaccination in this population subgroup.
The study was authored by Mamta K. Jain, Karen J. Vigil, Onkar Kshirsagar, Laura A. Hansen, Barbara S. Taylor, and Mae Thamer.
It is therefore regarded as a major global health problem because it can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer.
According to the World Health Organisation (WHO), an estimated 296 million people were living with chronic hepatitis B infection as at 2019, with 1.5 million new infections each year.
In 2019, hepatitis B resulted in an estimated 820,000 deaths.
About one percent of persons living with HBV infection, which estimates at 2.7 million people, are also infected with HIV. The global prevalence of HBV infection in HIV-infected persons is 7.4 percent.
But Hepatitis B can be prevented by vaccines that are safe, available and effective.
Since 2015, WHO has recommended treatment for everyone diagnosed with HIV infection, regardless of the stage of disease.
Tenofovir, which is included in the treatment combinations recommended as first-line therapy for HIV infection, is also active against HBV.
In conclusion, the study underlining the importance of recommending HBV vaccination in HBV seronegative PLWH even if they are on dual active HIV/HBV antiviral therapy is very critical.